Argonaut Therapeutics
Argonaut Therapeutics uses PRMT5 inhibitors and companion diagnostics for precision cancer treatment based on Oxford research.
Argonaut Therapeutics uses PRMT5 inhibitors and companion diagnostics for precision cancer treatment based on Oxford research.
Argonaut Therapeutics is a health care startup founded in 2016, which has received a significant $2.57M corporate round investment from JW Pharmaceuticals on 29 October 2018. The company, a spin-out of Oxford University's Medical Sciences Division, is dedicated to leveraging PRMT5 inhibitors and companion diagnostics for precision cancer treatment, building upon original research findings from Oxford. Their focus lies in identifying abnormal arginine methylation in advanced and metastatic tumors and establishing PRMT5 as a therapeutic target. Through the development of two unique series of PRMT5 inhibitors and proprietary companion diagnostics, Argonaut Therapeutics aims to deliver tailored and precise therapy for individual cancer patients.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Corporate Round | $2.57M | 1 | JW Pharmaceuticals | 29 Oct 2018 |
| Seed Round | Unknown | 1 |
|
01 Oct 2016 |
No recent news or press coverage available for Argonaut Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
